Kusajili – Clinical trials directory

Result of your search per sponsor: Janssen Alzheimer Immunotherapy

Woman and Man Max 99 years
Janssen Alzheimer Immunotherapy Update Il y a 5 ans

Study Evaluating the Efficacy and Safety of Bapineuzumab in Alzheimer Disease Patients Who are Apolipoprotein Eε4 non-carriers Primary Objective and Endpoints To demonstrate the efficacy of multiple doses of IV-administered bapineuzumab (bapineuzumab IV; 0.5- and 1.0-mg/kg) compared to placebo in subjects with mild to mode...

Country None
organs None
Specialty None

Closed trial

More information